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Abstract 
 
         Rheumatoid arthritis (RA) is a systemic inflammatory disease of unknown etiology. The 
rheumatoid  synovium  is  characterized  by  infiltration  of  T  cells,  macrophage,  B  cells,  and 
proliferating  fibroblasts  which  aggressively  invade  cartilage  and  bone,  thus  destroying  joints' 
ability to function. 
         In  rheumatoid  arthritis  (RA)  both  an  imbalance  between  excessive  production  of  the 
proinflamatory  and  ant-inflammatory  cytokines  and  skewing  of  the  T  cell  to  a  T  helper  like 
response.     
         Cytokines have  been shown  to  play a  modulatory  role in  the  pathogenesis of  RA.  The 
imunoregulatory  cytokine  IL-10  increases  autoantibody  production  by  B  cell  stimulates  its 
survival,  proliferation  and  differentiation.  Moreover  IL-10  inhibits  the  generation  of 
proinflamatory cytokines and proliferation of T helper lymphocyte.  
         Interleukin 16 might play a role in the pathogenesis of chronic inflammation in RA. It has 
a  proinflammatory  properties  by  promoting  recruitment  of  T  cells  into  the  rheumatoid 
synovium. Also IFN-γ is of interest because of the role it plays in the initiation and perpetuation 
of T helper cell . 
         Serum  level  of  IL-10,  IL-16,  and  IFN-γ  were  determined  in  patients  with  rheumatoid 
arthritis in relation to disease activity. 
         All patients with RA (n=30) showed highly significant increase in ESR, CRP, IL-10, IL-
16, IFNγ compared to control group (p<0.01). 
         Positive  correlation  were  found  between  IL-10  and  each  IL-16  and  IFN-γ  (p<0.001) 
(r=0.63,  0.55)  respectively,  and  highly  significant  correlation  between  IL-16  and  IFNγ 
(p<0.001) (r=0.89)were determined. 
         Results showed positive correlation between ESR and each IL-10, IL-16, IFNγ (p<0.001) 
(r=0.67, 0.87, 0.75) respectively. And highly significant correlation between CRP and each IL-
10, IL-16, IFNγ (p<0.001) (r=0.0.71, 0.83, 0.73) which indicate relation between increase level 
of cytokine with disease activity.  
         These  data  suggest  that  there  is  increased  production  of  IL-10,  IL-16,  and  IFN-γ  in 
patients  with  rheumatoid  arthritis,  and  that  it  is  correlated  with  the  disease  activity.  These 
cytokines  are  interesting  for  further  research  and  novel  therapeutic  approach  in  this 
inflammatory disease.  
        
Introduction 
 
         Rheumatoid  arthritis  (RA)  is  inflam-
matory disease of unknown etiology chara--
cterized by destruction of joints (Verhoef et 
al;2001).  Activation  and  infiltration  of 
immunologic  cells,  including  macrophage 
and lymphocytes, are prominent features of 
chronic  inflammation  in  rheumatoid 
arthritis (Scola et al;2002). 
         In  RA,  the  cytokines  resulting  from 
this cellular infiltration greatly influence the 
outcome  of  disease.  Macrophage  generally 
express  higher  levels  of  cytokines  than 
lymphocyte  in  RA,  while  the  lymphocyte 
contribution  to  inflammatory  and/or  joint 
destructive  process  may  be  more  indirect 
(Panayi et al;1992). 
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         Two subsets of T cells are recognized 
by their ability to produce different types of 
cytokines.  Th1  cell  activity  characterized 
by IFN-γ production participates in macro-
phage  activation  and  thereby  causes  joint 
destruction (Verhoef et al;2001) 
  Th2 cells selectively produces IL-4, 
IL-5, IL-6, IL-10 and IL-13, these cytokines 
mediate  transformation  of  B-  lymphocytes 
into  antibody  producing  plasma  cells 
(Libula et al;1995).The balance between T1 
and  T2  cells  regulates  the  production  of 
pro-  and  anti-inflammatory  cytokines 
(Verhoef et al;2001) 
         Systemic clinical signs of rheumatoid, 
such as the acute phase response (ESR, and 
CRP) in turn depend on the balance betw-
een these pro- and anti-inflammatory cytok-
ines (Littman et al;1995). 
         Interleukin-10(IL-10)  one  of  the 
cytokines which had been shown to exert a 
number  of  immunoregulatory  and  anti-
inflammatory  effect  in  RA  (Cush  et 
al;1995).  The  immunoregulatory  cytokine 
IL-10 increases autoantibody production by 
B  cells  from  RA  patients  (Reparon-Schujt 
et al;1998 and 2001)). 
         A  side  from  this  immunostimulatory 
function,  IL-10  inhibits  the  activation  and 
effectors functions of T cells, macrophage, 
and  monocytes  (Lard  et  al;2003).As  an 
anti-inflammatory  cytokine  IL-10  has  been 
shown to inhibit the synthesis  of IL-1α, IL-
1B, and TNF- α, IL-6, IL-8, IL-12, and IL-
18.  IL-10  also  inhibits  the  synthesis  of 
gelatinase  and  collagenase  (Oberholzer  et 
al;2002). 
         Interleukin -16 (IL-16) also known as 
lymphocyte  chemoattractant  factor,  is 
generally considered to play a decisive role 
in  most  immune  and  inflammatory  respo-
nses  (Kaufmann  et  al;2001)  in  rheumatoid 
arthritis  the  presence  of  IL-16  has  been 
described  in  synovial  tissues  from  patients 
with RA. However the functional activity of 
this T  cell  derived cytokine  in  the  pathog-
enesis of RA  is not completely  understood 
(Blaschke et al;2001). 
         Interferon-  gamma  (IFN-  γ)  is  a 
secretary product of activated T-cell of the 
Th1  subset  and  natural  killer  cells  (NK). 
INF-γ  is  produced  in  response  to  specific 
and non-specific immunologic activation of 
lymphocyte,  usually  T-lymphocytes 
(Boehm et al;1997). IFN- γ can down-regu-
late parameters of joint destruction such as 
IL-1, matrix  metalloproteinase  and  prolife-
ration of fibroblast- like synoviocytes (FLS) 
(Moller et al;2003). 
 
Aim of the work 
         Is to determine the level of IL-10, IL-
16,  and  IFNγ  in  serum  of  patients  with 
rheumatoid arthritis and assessing their role 
with disease activity. 
 
Patients and methods 
Subjects: 
         Our  study  included  30  patients  with 
rheumatoid  arthritis  and  10  healthy 
controls.  All  patients  were  selected  from 
patients attending internal medicine depart-
ment, Al Zahraa university hospital 
 Subjects were divided into 2 groups: 
 Group  I:  (RA  group):  30  patients  were 
fulfilling  The  1988  Revised  American 
Rheumatism  Association  (ARA) 
criteria  for  adults  RA  (Arnett,  et  al 
1988))  22  were  female  and  8  were 
males.  
         Their  Age  ranged  from  17-50  years 
with a mean of (28.3± 9.7).  
         Duration  of  disease  ranged  between 
2.5 and 9 years with mean (5.2 ±2). 
         Morning stiffness  ranged between  18 
and 90 minute, with mean (19 ± 2).           
         Articular  index  score  (AIS)  ranged 
between 22 and 27 with mean (24.8 ± 
1.7)                   
 Group II: (Control group): 10 healthy age 
and sex matched volunteers; they were 
selected from  medical and  paramedical 
staff  of  the  hospital,  2  males  and  8 
females. Their Age ranged between 19-
51 years with mean (31.7 ±9.7).           
 
All patients and controls were submitted 
to the following: 
1- Complete history taking and full clinical 
examination 
2-Routine  laboratory  investigations 
including: 
  Complete  blood  picture  by  automated 
blood counter. 
  Assessment  of  ESR  in  the  first  hour 
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  Latex rheumatoid factor 
  C-reactive protein (CRP level) 
  Fasting blood sugar, liver function tests 
and  kidney  function  tests,  using 
Bohringer  Mannheim  Company  photo-
metric  kits  West  Germany  on  Hitachi 
911 auto analyzer. 
3-  Specific  laboratory  investigations 
including: 
1.  Serum IL-10 by ELISA 
(II)      Serum IL-16 by ELISA 
2.  Serum INF-γ by ELISA 
 For  this  purpose  blood  samples  from 
patients  and  control  were  taken  at  the 
morning  to  avoid  the  influence  of  the 
time  of  the  day  on  lymphocyte  respo-
nses  and  cytokines.  About  5cc  of 
venous  blood  was  drawn  and  centri-
fuged for about 10 minutes and serum 
was separated, taken and stored at-20c° 
until time of analysis. 
         Cytokines  concentration  were  mea-
sured  in  serum  using  a  commercially 
available  monoclonal  antibody  based 
sandwich  ELISA  kit  (Biosourse  Europe 
S.A)  for  human  IL-10,IL-16  and  INF-  γ. 
Briefly,  standards,  samples,  and  controls 
tested  sera  were  pipetted  into  wells  pre-
coated  with  murin  monoclonal  antibodies 
raised  against  each  parameter  followed  by 
addition  of  horse  radish  peroxidase 
antibodies  to  each  parameter.  After  an 
incubation period allowing the formation of 
a sandwich, coated Mab1+Mab2 HRP. 
         The  microtiter  plate  was  washed  to 
remove  unbound  enzyme  labeled  antibo-
dies.  Bound  enzyme  labeled  antibodies 
were  measured  through  a  chromogenic 
reaction.  Chromogenic  solution  (TMB+ 
H2O2)  was  added  and  incubated.  The 
reaction  stopped  with  the  addition  of  stop 
solution(H2SO4)  and  the  microtiter  plate 
was then read at  450nm wave length.  The 
level  of  IL-10,  IL-16  and  INF  γ  were 
calculated  from  standard  curve  corresp-
onding  to  the  measured  optical  densities. 
The results expressed as pg/ml.  
         All  RA  patients  met  the  American 
College  of  Rheumatology  (ACR)  1987 
revised criteria for the classification of RA 
(Arnett  et  al;  1988).  The  disease  activity 
comprised  assessment  of  morning  stiffness 
(MS)  duration  in  minutes,  articular  index 
scor (AIS) (joint tenderness) it is measured 
using The Ritchia articular index (Ritichia, 
et al, 1968), ESR in the first hours hemog-
lobin  percentage  (Hb%)  and  radiological 
examination of the affected joints. 
 
Statistical analysis   
         Results  were  tabulated  and 
statistically  analyzed  through  Compaq 
computer.  The  value  were  given  as  mean 
±SD.  Comparison  of  the  values  were 
performed using the unpaired student T test 
and  one  tailed  P  value  is  considered 
significant when it is <0.05. 
 
Results 
 
         Baseline  clinical  and  laboratory 
characteristic  of  the  studied  groups  is 
provided in table(1). 
         Table  (1)  show  the  criteria  of  RA 
(Age,  duration  of  disease,  morning  stiff, 
tender  joint,  swollen  joint  count,  articular 
index score (AIS). 
         Table(2)  and  fig(1,2,3)  show  that 
There  was  highly  significant  increase  in 
ESR, CRP in patients with RA compared to 
control  group  (P<0.001)  .Also  there  was 
highly significant  increase  in  serum  IL-10, 
IL-16, IFNγ in patients with RA compared 
to control group (P<0.001).  
         Table  (3)  shows  correlation  between 
serum IL-10 and each Hb, ESR, CRP, IL-
16, IFNγ in group I (30 patients with RA). 
There  was  highly  significant  correlation 
between S. IL10 and each of ESR, CRP, IL-
16,  IFNγ  (p=<0.001)  (r=0.67,  0.71,  0.63, 
0.55) respectively. Also there was negative 
significant correlation between S.IL-10 and 
Hb  (p=<0.001)  (r=0.74).  Fig  4  show 
positive correlation between  IL-10 and  IL-
16 among group 1. 
         Fig  5  show  positive  correlation 
between IL-10 and IFNγ among group 1 
         Table  (4)  show  correlation  between 
serum IL-16 and each Hb, ESR, CRP, IFNγ 
in group I (30 patients with RA). There was 
highly  significant  correlation  between  S. 
IL16  and  each  of  ESR,  CRP,  IFNγ 
(p=<0.001)  (r=0.87,  0.83,  0.89,)  respect-
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correlation  between  S.IL-16  and  Hb 
(p=<0.001) (r=0.89). 
         Fig  6  show  positive  correlation 
between IL-16 and IFNγ among group 1. 
         Table  (5)  show  correlation  between 
serums IFNγ  and each  Hb, ESR,  CRP,  in 
group I  (30 patients  with RA).  There  was 
highly significant correlation between IFNγ 
and each of ESR, CRP, (p=<0.001) (r=0.75, 
0.73)  respectively.  And  also  there  was 
negative  correlation  between  IFNγ  and  Hb 
(p=<0.001) (r=0.80). 
 
Table (1): Clinical and biochemical data for 30 patients with rheumatoid arthritis (group 
1) and 10 control subject 
 
parameter  Group I patients with RA 
N=30 mean ±SD 
Group II control 
N=10 mean ±SD 
Age (years) 
 
28.3 ± 9.7  31.1 ±9.7 
Duration of disease 
(years) 
5.2 ± 2  _____ 
Morning stiff 
(minuets) 
19 ± 3.2  ______ 
Tender joint 
 
9.4 ± 2  _______ 
Swollen joint count 
 
3.6 ± 1.4  _______ 
AIS 
 
14.8 ±1.7  _________ 
Hemoglobin 
(g/dl) 
10.5 ±  1.1  12.5 ± 4.7 
ESR 
(mm/h) 
60 ± 30  15± 4 
CRP 
(mg/l) 
34.1 ± 12.6  1.8 ± 0.4 
IL-10 
(pg/ml) 
27.9 ± 5.6  2.27 ± 0.3 
IL-16 
(pg/ml) 
60.7 ± 41.4  3.2 ± 0.6 
IFN-γ 
(pg./ml) 
83.5 ± 16.8  12.6±  2.8 
 
Table 2:Mean values of laboratory variables in patients with RA(group I) as compared to 
control group (group II). 
 
parameter  Group I 
mean ±SD 
Group II mean 
±SD 
P value  T value  significance 
Hemoglobin 
(g/dl) 
10.5 ±1.1  12.5 ±4.7  <0.01  7.9  HS 
ESR 
(mm/h) 
60± 30  15±4  <0.01  3.8  HS 
CRP 
(mg/l) 
34.1 ±12.6  1.8 ±0.4  <0.01  1  HS 
IL-10 
(pg/ml) 
27.9 ±5.6  2.27 ±0.3  <0.01  9.2  HS 
IL-16 
(pg/ml) 
60.7±  41.4  3.2 ±0.6  <0.01  1.2  HS 
IFN-γ 
(pg./ml) 
83.5 ±16.8  12.6±2.8  <0.01  1.1  HS 
 Interleukin-10, Interleukin- 16 and Interferon-γ…….. 
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Table  (3):  Correlation  between  IL-10  and  each  hemoglobin  level,  erythrocyte 
sedimentation rate, C reactive protein, IL-16, and IFNγ in (group I) 30 patients 
with RA  
 
 
 
 
IL-10 
 (pg./ ml) 
parameter  R value  P value  significance 
Hemoglobin 
(g/dl) 
- 0.74  <0.001  HS 
ESR 
(mm/h) 
0.67  <0.001  HS 
CRP 
(mg/l) 
0.71  <0.001  HS 
IL-16 
(pg/ml) 
0.63  <0.001  HS 
IFN-γ 
(pg./ml) 
0.55  <0.001  HS 
 
Table  4):  Correlation  between  IL-16and  each  of  hemoglobin  level,  erythrocyte 
sedimentation rate, C reactive protein, and IFNγ in 30 patients (group I) with RA 
 
 
 
 
IL-16 
 (pg./ ml) 
parameter  R value  P value  significance 
Hemoglobin 
(g/dl) 
- 0.89  <0.001  HS 
ESR 
(mm/h) 
0.87  <0.001  HS 
CRP 
(mg/l) 
0.83  <0.001  HS 
IFN-γ 
(pg./ml) 
0.89  <0.001  HS 
 
Table  (5):  Correlation  between  IFNγ  and  each  hemoglobin  level,  erythrocyte 
sedimentation rate, C reactive protein in (group I) 30 patients with RA  
 
 
 
 
 
IFN-γ 
(pg./ ml) 
parameter  R value  P value  significance 
Hemoglobin 
(g/dl) 
- 0.80  <0.001  HS 
ESR 
(mm/h) 
0.75  <0.001  HS 
CRP 
(mg/l) 
0.73  <0.001  HS 
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Fig(1) Mean values of IL-10 in rheumatoid arthritis group and control group 
 
 
 
 
Fig (2) Mean values of IL-16 in patients with rheumatoid arthritis and control group. 
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Fig (3) Mean values of IFNγ in patients with rheumatoid arthritis and control group 
 
 
 
 
 
Fig (4) Positive correlation between IL-10 and IL-16 among group 1 
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Fig (5) Positive correlation between IL-10 and IFNγ among group 1 
 
 
 
 
 
Fig (6)  Positive correlation between IL-16 and IFNγ among group 1 
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Discussion 
         
         Arthritis and joint destruction are the 
hallmarks of rheumatoid arthritis (RA). The 
progression  of  joint  destruction  varies 
considerably  among  patients  with  RA 
(Huizinga et al; 2000). 
         Proinflammatory  cytokines  play  a 
significant  pathogenic  role  in  RA.  Anti-
inflammatory  cytokines  can  also  be  found 
in  the  affected  joints  and  it  has  been 
postulated  that  chronic  synovitis  may 
reflect  an  imbalance  in  pro-  and  anti-
inflammatory  cytokine  production  in  RA 
(Weckmann et al; 1996). Consequently, the 
potential  effect  of  anti-inflammatory 
cytokines such as IL-10 in RA is of  great 
interest (Mackay et al; 2003). 
         Various  lines  of  research  suggest  an 
important role of IL-10 in the pathogenesis 
of  joint  destruction  in  RA.  Other  studies 
show  that  IL-10  inhibits  the  generation  of 
proinflammatory  cytokines  and  the 
proliferation of Th1 lymphocytes. 
         IL-16  is  a  T  cell  derived  cytokine 
originally  identified  and  purified  as 
lymphocyte  chemoattractant  factor.IL-16 
acts  via  the  CD4  molecule  as  its  receptor 
and exert a broad spectrum of both pro- and 
anti-inflammatory  biologic  activities 
(Blaschke et al; 2001). 
         Interferon-  gamma  (IFN-  γ)  is  a 
secretary product of activated T-cell of the 
Th1  subset  and  natural  killer  cells  (NK). 
INF-γ  is  produced  in  response  to  specific 
and non-specific immunologic activation of 
lymphocyte,  usually  T-lymphocytes 
(Boehm et al; 1997).   
         In  the  present  study  plasma  level  of 
IL-10, IL-16, and IFN-γ were measured in 
30 patients with rheumatoid arthritis comp-
ared  to  10  sex  and  age  matched  normal 
subjects. 
         Our  results  show  highly  significant 
increase in serum IL-10 in patients with RA 
compared  to  control  group.  Our  results 
agree  with  Cush  et  al;  (1995)  who  found 
serum  and  synovial  fluid  (SF)  contained 
significantly elevated IL-10 level compared 
to control group. On other hand Verhoef et 
al;  (2001)  found  IL-10  production  was 
statistically  higher  in  patients  group  with 
mild disease compared to severe disease. 
         Also  our  results  show  highly  signif-
icant  positive  correlation  between  serum 
IL-10  and  each  of  ESR,  CRP.This  result 
disagree with Cush et al;( 1995 ) who found 
no  correlation  was  demonstrated  between 
IL-10 levels and most clinical measures of 
disease  activity  (age,  disease  duration, 
morning  stiffness,  patients  and  physician 
global  assessment,  swollen  or  tender  joint 
counts.  Also  they  reported  no  significant 
difference was noted between those patients 
treated or not treated with prednisone. But 
Verhoef  et  al;  (2001)  found  negative 
correlations  between  IL-10  production  and 
ESR, CRP, and strong negative correlation 
with  radiographic  joint  damage  as  well  as 
progression of joint damage.  
         In the present study serum level of IL-
10 show highly significant correlation with 
each  serum  level  of  IL-16  and  IFNγ,  this 
results show disagreements with the results 
of  Verhoef et al; (2001) they reported no 
correlation between IL-10 and IFNγ. 
         Lard et al; (2003) reported that IL- 10 
genotype  was  not    associated  with  the 
incidence  of  RA,  but  instead  ,correlated 
with disease progression, as determined by 
extent of joint destruction. 
         Our  results  show  highly  significant 
increase in serum IL-16 in patients with RA 
compared to control group. And also show 
highly significant positive correlation betw-
een serum IL-16 and each of ESR, CRP. 
         Our data show agreements  with that 
of Blaschke et al; (2001 ) who detect that 
IL-16  was  significantly  high  in  sera  and 
synovial  fluid  of  patients  with  RA  in 
comparison to  osteoarthritis and  to  normal 
control,  also  they  reported  the  lack  of 
significant  correlation  between  IL-16 
expression,  clinical  disease  activity,  and 
local  inflammatory  activity  suggesting  a 
regulatory  rather  a  pro-inflammatory 
function  for  IL-16  in  the  pathogenesis  of 
chronic synovial inflammation in RA.  
         These  finding  for  IL-16  differ  from 
cytokines   with   predominant  proinflam- Eman.M.Abdel Rahman et al   
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matory activity in RA, such as TNF-α, IL1-
B, and IL-6, also OKamoto et al; ( 1997) 
have  described  increased  serum  levels  of 
these  macrophage  derived  cytokines  and 
significant  correlation  between  serum 
cytokine  concentration  and  disease  activity 
in RA. 
         Kaufmann et al; ( 2001) found serum 
level of IL-16 in RA was increased signifi-
cantly compared with non RA control, and 
in RA patients and controls, there were no 
significant  differences  in  cytokine  level 
with respect to age and sex. And also they 
reported that a level of IL-16 was correlated 
with ESR and C-reactive protein.   
         Our  results  show  highly  significant 
increase in serum IFNγ in patients with RA 
compared to control group. And also show 
highly significant positive correlation betw-
een serum IFNγ and each of ESR, CRP. 
         This  result  agree  with  Kanik  et  al; 
(1998)  who  found  increased  production  of  
IFNγ in RA patients with new onset syno-
vitis,  in  contrast  to  patients  with  chronic 
RA who had increased IL-16 production. 
         Verhoef  et  al;  (2001)  reported  no 
correlation between IFNγ with disease acti-
vity variables (ESR, CRP) or joint damage 
and that may be due to use of medication, 
and also found negative correlation between 
IFNγ and age of RA patients. 
         Scola et al; (2002) found that juvenile 
RA (JRA) has generally been described as a 
type I disease with increased level of IFNγ 
and  variably  low  IL-4  in  study  utilizing 
synovial  fluid,  and  also  confirm  continued 
expression of IFNγ/IL-4 ratio compared to 
that of control tissue, but also they reported 
no  significant  difference  in  the  expression 
of IL-10 in JRA from that controls, possibly 
indicating a loss of regulation in severe or 
long standing disease.  
         Bas et al; (2003) found SF concentr-
ations of IL-10 were significantly lower in 
patients  with  reactive  arthritis  than  RA 
patients.  The  SF  level  of  IFNγ  was  not 
significantly different but the ratios of IFNγ 
to  IL-10  were  significantly  higher  in 
patients with reactive arthritis. 
 
Conclusion 
         These  data  suggest  that  there  is 
increased  production  of  IL-10,  IL-16,  and 
IFN-γ in patients with rheumatoid arthritis, 
and that is correlated with disease activity. 
These  cytokines  are  interesting  for  further 
research and novel therapeutic approach in 
this inflammatory disease.  
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 هيكىيلرتوا 01     هيكىيلرتوا و 01  نايثرلا ضرم يف اماج نوريفرتوا و
يلصفملا  
  ىضرملا طاشىلاب اهتقلاعو  
همحرلا دبع دمحم ناميإ * تزع ةيدمح ،  ** هسحملا دبع دمحم اهم ، **  ةميرك،
فسىي  *  
تهاعلا تٌطابلا نسق * تيكيٌلكلاا ايجْلْثابلا ، ** رُزلأا تعهاج ثاٌب بط تيلك  ،  
 
 داا دعلا ااااٌُ  مابااالأا يااكلّ بلاالأاولا ىااايثرلا نرااول تاالوخةولا مابااالأا يااه
 تااا ّااويللا اااا   لا ى  ةدْااال داااقلا  ،ىنا ٔاااخد ااااِب اااا ْهقه عيااال تااايقيقةلا T    ّ B    ّ
 ٔااابيكرخلا اااال لا  ْاااِ  ٔااالر ٓاْاااخلا ،بلااالأاولا ٔاااليلسلا  اااازللا اااال خح تاااالاّركيولا
صااولاّ ف  اضللا تلاد ٔل  رثْح كلذكّ  ازللا اذِل باي ْلاّ  اااٌُ ى  ييابح دقّ ا
 ،مااِخللاا ثااااضهّ مااِخللاا ثابباسه ياه دا اسخولا تاخًلإا ييب ىزاْخلا مد  يه تلاد
ييكْايلرخًا  اثه ت ْل لا رئازعلا بعلخلا 01    ااصااولل ٔالرولا  ْاهخلا بالا ااهاُ ا ّا
ب اٌولا زاِجلا ٔل  ريثأخلا كلذكّ .  
 ييكْيلرخًا بعل ّ 01   ولا ٔلرولا  ْهخلا بلا اهاُ ا ّا  ثلاااةلا ٍذُ بلا يهس
 ااا   ل تهاازٌه ةئااالأص َاال ىر إاايد T     ىا اااوك َاايليلسلا تياازللأا ٔاال  رثعااح بااخلا
 ا  ص ٔل  اض   اهزٌه ا ّا بعل  اهاج ى ْيلارخًا T    ةد اسولا .  
 ييكْيلرخًا ْٓخسه ايلةح نح دقّ 01    ييكْايلرخًا ّ ( 01  )  بالا ااهاج ى ْايلارخًاّ
اِ   دقّ ٔلرولا طازً تج ا نييقخل ٔلرولا  تيئاالأدر تاللاا ثات ذاااح ا  ئااخٌلا ثر
 ييحّراابّ بيااارخلا ت رااا يااه اااك باالا C    ييكْاايلرخًاّ ظاازٌلا 01    ييكْاايلرخًا ّ 01  
 ياه ااك يياب تعاحره تيئالأدر تللاا ثات َيطابح ا تق   اْجّ جبثّ اهاج ى ْيلارخًاّ
 ييكْيلرخًا 01   ييكْيلرخًاّ     01   اب تايطابح ا تاق   ااض   دجْ  اوك اهاج ى ْيلارخًا  يي
 ييكْيلرخًا 01  ييكْايلرخًا ياه ااكّ بياارخلا ت راا يياب كلذاكّ ااهاج ىْيلارخًا ّ 01  
 ييكْلرخًاّ 01   اهاج ىْيلارخًاّ .  
 ييحّرب ييب تيئالأدا تللاا ثات تيطابح ا تق   اْجّّ C    يه اكّ ظزٌلا
 ييكْيلرخًا 01   ّ  هيكىيلرتوا   01    ييب تق   اْجّ ٔلر ريز  اوه اهاج ىّريلارخًاّ
ْخسه ذااح ا نرولا طازً تج اّ ت ْل لا رئازعلا ٓ .  
 